Proton-pump inhibitors for the treatment of functional dyspepsia

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 4, 2011, Pages 219-226

  Suzuki, Hidekazu ^a   Okada, Sawako ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisecretory agents; Functional gastrointestinal disorders; Helicobacter pylori; Randomized controlled study; Uninvestigated dyspepsia

Indexed keywords

ESOMEPRAZOLE; ITOPRIDE; LANSOPRAZOLE; MOSAPRIDE CITRATE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

COMPARATIVE STUDY; DYSPEPSIA; ENDOSCOPY; EPIGASTRIC DISCOMFORT; EPIGASTRIC PAIN; ESOPHAGOGASTRODUODENOSCOPY; FUNCTIONAL DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; NON EROSIVE REFLUX DISEASE; PLACEBO EFFECT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLUX ESOPHAGITIS; REVIEW; SCORING SYSTEM; STOMACH EMPTYING; SYSTEMATIC REVIEW; TERTIARY HEALTH CARE;

EID: 79959562285     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11398735     Document Type: Review

References (23)

1. Bolling-Sternevald E. Lauritsen K. Talley N.J. Junghard O. Glise H. (2003) Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 18: 117–124.
2. Chiba N. Thomson A.B. Sinclair P. (2000) From bench to bedside to bug: an update of clinically relevant advances in the care of persons with Helicobacter pylori-associated diseases. Can J Gastroenterol 14: 188–198.
3. Ghosh A. Halder S. Mandal S. Mandal A. Basu M. Dabholkar P. (2008) Rabeto plus: a valuable drug for managing functional dyspepsia. J Indian Med Assoc 106: 752–754.
4. Grudell A.B. Camilleri M. Burton D.D. Stephens D.A. (2006) Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment Pharmacol Ther 24: 1037–1043.
5. Kleibeuker J.H. Thijs J.C. (2004) Functional dyspepsia. Curr Opin Gastroenterol 20: 546–550.
6. Miyamoto M. Manabe N. Haruma K. (2010) Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med 49: 1469–1476.
7. Moayyedi P. Delaney B.C. Vakil N. Forman D. Talley N.J. (2004) The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 127: 1329–1337.
8. Mundo-Gallardo F. de Mezerville-Cantillo L. Burgos-Quiroz H. Izquierdo E. Chang-Mayorga J. Azteguieta L. et al (2000) Latin American open-label study with rabeprazole in patients with functional dyspepsia. Mexican Rabeprazole Investigators Group. Adv Ther 17: 190–194.
9. Peura D.A. Kovacs T.O. Metz D.C. Siepman N. Pilmer B.L. Talley N.J. (2004) Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 116: 740–748.
10. Reimer C. Bytzer P. (2010) Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. Eur J Gastroenterol Hepatol 22: 1182–1188.
11. Reimer, C., Sondergaard, B., Hilsted, L. and Bytzer, P. (2009) Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterol 137: 80–87.
12. Sanaka M. Yamamoto T. Kuyama Y. (2010) Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci 55: 2431–2440.
13. Schwartz M.P. Samsom M. van Berge Henegouwen G.P. Smout A.J. (2001) Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia. Aliment Pharmacol Ther 15: 1921–1928.
14. Suzuki H. Hibi T. Marshall B.J. (2007) Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 42: 1–15.
15. Suzuki H. Nishizawa T. Hibi T. (2006) Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 41: 513–523.
16. Tack J. Talley N.J. Camilleri M. Holtmann G. Hu P. Malagelada J.R. et al (2006) Functional gastroduodenal disorders. Gastroenterology 130: 1466–1479.
17. Talley N.J. Lauritsen K. (2002) The potential role of acid suppression in functional dyspepsia: the bond, opera, pilot, and encore studies. Gut 50(Suppl. 4): iv36–iv41.
18. Talley N.J. Locke G.R. Lahr B.D. Zinsmeister A.R. Cohard-Radice M. D'elia T.V. et al (2006) Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 23: 923–936.
19. Talley N.J. Meineche-Schmidt V. Pare P. Duckworth M. Raisanen P. Pap A. et al (1998) Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 12: 1055–1065.
20. Thompson W.G. (2000) Placebos: a review of the placebo response. Am J Gastroenterol 95: 1637–1643.
21. van Zanten S.V. Armstrong D. Chiba N. Flook N. White R.J. Chakraborty B. et al (2006) Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled Enter trial. Am J Gastroenterol 101: 2096–2106.
22. Veldhuyzen van Zanten S.J. Chiba N. Armstrong D. Barkun A. Thomson A. Smyth S. et al (2005) A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the Cadet-HN study. Am J Gastroenterol 100: 1477–1488.
23. Wong W.M. Wong B.C. Hung W.K. Yee Y.K. Yip A.W. Szeto M.L. et al (2002) Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 51: 502–506.